Description: With recent and continuing changes in regulatory requirements under VM-20, new accounting standards under GAAP LDTI/IFRS 17, expansion of accelerated underwriting programs and digital distribution, and the impact of COVID-19, the needs and challenges being faced by life insurance companies are greater and more varied than ever. Both under favorable and stressed conditions, companies heavily rely on reinsurance and the market has seen several major transactions enacted in this space over recent months. Reinsurance offers a wider variety of opportunities for companies to manage their balance sheets and increase their return on capital. Find out how reinsurance can be utilized to address the challenges associated with earnings growth and volatility, risk management, capital allocation efficiency, and product performance optimization. Moreover, upon enacting a transaction, ensuring the implementation of effective reinsurance operations is crucial to avoid operational inefficiencies and monitor the transaction's performance. Understanding the potential opportunities and common pitfalls in the reinsurance processes is vital for capturing the full value of reinsurance. By attending the session, you will be able to understand the various challenges being faced by direct writing companies today and where reinsurance can be leveraged to improve capital and tax position, as well as achieving the optimal balance of risk appetite and underwriting profit. Additionally, the presentation will provide real life case studies on how innovation and operational excellence can improve earnings by reducing costs related to inefficiencies, reducing process timing, improving controls, and reducing reinsurance leakage.

Description: This session series is sponsored by Hannover Re Session 2 - COVID-19: Financial Impacts and Re-shaping Risk and Capital Management Practices COVID-19 has posed significant challenges to health insurers and providers to meet profit targets and maintain strong balance sheets and capitalization levels. As a result, companies are facing an ever-increasing need to better integrate their risk and capital management practices across the enterprise and evaluate a broader set of tools to manage and optimize their capital and liquidity needs. This second session of the COVID-19 series will help you examine the financial impact that COVID-19 has had on the health industry and review how companies are evolving their financial and capital management practices to achieve their strategic goals. It will also outline how structured reinsurance has emerged as an increasingly utilized form of managing capital. By attending this session, you will be able to explain how COVID-19 has impacted the financial performance and capitalization of the health insurance industry, and will gain a basic understanding of alternative ways of managing and optimizing capital, including the use of structired reinsurance.

Description: LDTI requires that reinsurance recoverables be recognized in a manner consistent with the liabilities of underlying direct contracts. Consider implications of multiple ceded reinsurance contracts (e.g., coinsurance and YRT on the same business) and how this impacts the calculation of the net premium ratio (NPR) and other related approximations. Explore different options when only some of the policies within a cohort are reinsured. Multiple interpretations of the components of the NPR formula exist. Two main approaches will be presented-standalone and integrated approach. Other considerations to be discussed include implications of closed-block reinsurance transactions at transition and subsequent to transition, contra-DAC, market risk benefits. Finally, explore the short-duration YRT approximation (1/2 Cx) compared to the long-duration calculation.

Description: Gene therapy is a quickly evolving field and will continue to grow as a risk concern for many health plans, stop loss insurers and reinsurers. Currently, there are only two approved gene therapies in the U.S., but that number is expected to escalate starting in the fall of 2022. Revisit the experience plans have had with the first two gene therapies, discuss plan design and network considerations in light of gene therapy, and discuss the actual composition of the near-term pipeline along with a range of modeled financial impacts and considerations for payers.

Description: ClubVita Session Series Longevity trend risk still exists even for the largest portfolios. Explore the differences in longevity improvements between different populations, how to categorize subpopulations with different trend risk characteristics, and how to use this categorization to reduce longevity trend basis risk.

Description: Learn about considerations and industry observed trends which cover different ways companies try to manage their inforce business in low and rapidly rising interest environments. You will explore M&A, block transaction, and offshore reinsurance solutions.

Description: Look beyond traditional reinsurance arrangements. Strategically crafted reinsurance structures can support new business and achieve a wide range of risk management and financial objectives. Consider creative ways to look holistically at your business to develop the most effective solutions. Combine in-force and new business? Yes! Individual and group? Of course. Multiple product types? That can work! Whether you are trying to free up capital, address an underperforming block or venture into a new line of business, there are reinsurance structures that can help. Look at a virtual case study with a panel of experts and consider the options for selecting and structuring a reinsurance transaction. View key elements such as scale, composition and market appetites. Look at a variety of products including life, annuity, PRT and long-term care. The panel includes representation from a carrier, a reinsurer and a reinsurance broker. Get the opportunity to weigh in on decision points using online polling software, whether in person or virtual.

Description: ClubVita Session Series Buyouts and indemnity swaps remove all the longevity risk from an underlying population. However, they can be difficult to unwind and are not very flexible or widely tradable. Explore the characteristics and product structures of indexed based longevity swaps, demonstrating how they can cover any term, how they hedge the key component of trend risk and how, with new technology developments, they could lead to a liquid market.

Description: Join a discussion on the tax implications for direct writers ceding annuity blocks for both onshore and offshore reinsurance arrangements. Get an introduction to the tax consequences of the risk transfer of annuity features and guarantees to reinsurers to reinsurers that are U.S.-based and not U.S. domiciled.

Description: Review the Bermuda Monetary Authority's Consultation Paper I and focus on required changes to governance, risk management, modeling, lapse risk, filing requirements, model governance and more.